SOBI 1st-qtr 2015 results way ahead of analysts’ forecasts
Nordic biotech firm Swedish Orphan Biovitrum (STO: SOBI) announced this morning that revenues for the first quarter of 2015 have leapt 39% (on a constant exchange basis) to 865 million Swedish kronor ($103.3 million), well ahead of the 695 million kronor expectations of analysts polled by Reuters.
Product revenue was 633 million kronor, up 40% (at CER). Earnings before interest, taxes and amortization (EBITA) came in at 172 million kronor, compared to a loss of 288 million kronor for the like quarter of 2014, more than double the 695 million kronor expected by analysts. Gross margin was 60% compared with 56% a year earlier.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze